| abstract |
Pharmaceutical compositions comprising an isolated form of anatabine or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. In another aspect, methods for the synthetic preparation of anatabine involve reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. |